Dr. Tiffany Troso-Sandoval MD Medical Oncologist

Dr. Tiffany Troso-Sandoval is a medical oncologist in Commack, New York. She is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Mercy Medical Center. She received her medical degree from Weill Cornell Medical College of Cornell University and has been in practice for 14 years. Dr. Troso-Sandoval accepts several types of health insurance, listed below. She is one of 120 doctors at Memorial Sloan-Kettering Cancer Center and one of 10 at Mercy Medical Center who specialize in Medical Oncology.

Are you Dr. Tiffany Troso-Sandoval? Claim your profile to make edits or add details. Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology

Hospital Affiliation

Memorial Sloan-Kettering Cancer Center
Ranked #2 in Cancer

Mercy Medical Center

Education & Medical Training

New York Presbyterian Hospital
Residency, Internal Medicine, 1996 - 1999

Memorial Sloan-Kettering Cancer Center
Fellowship, Hematology/Oncology, 1999 - 2001

Weill Cornell Medical College of Cornell University
Class of 1996

Certifications & Licensure

American Board of Internal Medicine
Certified in Internal Medicine

American Board of Internal Medicine
Certified in Medical Oncology

NY State Medical License

Publications & Presentations

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster, P. N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P. A., Richon, V. M.

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang, C., Fornier, M., Sugarman, S., Troso-Sandoval, T., Lake, D., D'Andrea, G., Seidman, A., Sklarin, N., Dickler, M., Currie, V., Gilewski, T., Moynahan, M. E., Drullinsky, P., Robson, M., Wasserheit-Leiblich, C., Mills, N., Steingart, R., Panageas, K., Norton, L., Hudis, C.

Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
Drullinsky, P., Sugarman, S. M., Fornier, M. N., D'Andrea, G., Gilewski, T., Lake, D., Traina, T., Wasserheit-Lieblich, C., Sklarin, N., Atieh-Graham, D., Mills, N., Troso-Sandoval, T., Seidman, A. D., Yuan, J., Patel, H., Patil, S., Norton, L., Hudis, C.

See all 6 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • BCBS Kansas City Preferred-Care Blue PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Empire BCBS HMO
  • Empire BCBS PPO
  • First Health PPO
  • GHI PPO
  • Great West PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • MVP Healthcare PPO
  • Oxford Health Freedom
  • Oxford Health Liberty
  • QualCare HMO
  • QualCare PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by

Specialty

Location

Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.